GUARD Model: Executive Intelligence Brief

Guarding U.S. Medicare Against Rising Drug Costs

ValuesEdge Strategic Analysis | Based on CMS GUARD Model Page (Last Modified: December 29, 2025)

---

1. Executive Summary and Strategic Context

What Is This Model and What Problem Does It Solve?

The Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model is a proposed mandatory model under development by the CMS Innovation Center (CMMI), operating under authority granted by Section 1115A of the Social Security Act. GUARD is currently in the "Announced" stage, pending finalization of a Notice of Proposed Rulemaking (NPRM) published in the Federal Register, with a public comment deadline of February 23, 2026.

The model targets a well-documented and escalating structural problem in the Medicare drug benefit: the growing price gap between what the United States pays for prescription drugs and what economically comparable countries pay for the same medications. Total Medicare Part D gross drug spending increased from $121 billion in 2014 to $276 billion in 2023, representing a compound annual growth rate of nearly 10% per year. By 2024, Part D drug spending accounted for approximately 30% of total gross drug spending in the United States — a fiscal trajectory that directly threatens both beneficiary affordability and the long-term solvency of Medicare.

The mechanism GUARD deploys is a modification to the existing Medicare Part D Inflation Rebate Program. Under current law, that program calculates manufacturer rebates against a domestic benchmark. GUARD would substitute an international price benchmark — derived from prices paid by countries meeting certain GDP per capita and minimum real economy size thresholds — in place of the domestic comparator. When a drug's U.S. price exceeds the international benchmark, the manufacturer would owe a rebate to the Medicare Supplementary Medical Insurance (SMI) Trust Fund. This rebate mechanism would effectively compress the net cost Medicare pays for targeted drugs toward the price levels prevailing in comparable high-income economies.

The model explicitly addresses the downstream clinical and economic consequences of drug unaffordability: skipping doses, cutting dosages, and non-adherence among older adults with Medicare Part D coverage — behaviors that frequently produce higher-severity disease progression, emergency department utilization, and hospitalization costs that ultimately cost Medicare more than the medications themselves.

Strategic Significance for the Value-Based Care Market

GUARD is not a provider-facing model — health care providers are not participants and it does not qualify as an Advanced Alternative Payment Model (APM) or MIPS APM under the Quality Payment Program. Nonetheless, its strategic implications for the broader value-based care market are substantial and multidirectional.

For ACOs and integrated delivery systems, GUARD's core promise is improved medication adherence among the Medicare Part D population. ACOs bearing downside risk on total cost of care have a direct financial stake in reducing the high-acuity care events that flow from non-adherence. If GUARD succeeds in reducing out-of-pocket drug costs, it could meaningfully lower the rate of preventable hospitalizations and ED visits that drive shared loss calculations — effectively making GUARD a downstream enabler of ACO performance even though providers are not in the participant seat.

For Medicare Advantage plan strategists, GUARD's geographic targeting creates a critical market signal. Because the model would apply only in randomly selected geographic areas representing 25% of people who have a Medicare Part D plan, MA plan operators will need to monitor whether their service areas fall within or outside the GUARD footprint. Plans operating in GUARD-affected markets could see shifts in Part D cost dynamics, formulary pressures, and competitive positioning relative to stand-alone PDP competitors.

For pharmacy benefit managers and plan sponsors, the modification to the inflation rebate calculation represents a direct intervention in the contractual ecosystem governing drug pricing. The displacement of a domestic benchmark with an international one rewrites the reference point for an entire class of sole-source drugs and sole-source biologics across 17 named therapeutic categories — a scope broad enough to affect formulary construction, tier placement strategy, and preferred pharmacy negotiations.

Political Context and Administrative Alignment

GUARD was published as an NPRM with the public comment period closing February 23, 2026 — meaning its trajectory will be shaped entirely by the Trump administration, with CMS under Administrator Dr. Mehmet Oz and CMMI under Director Abe Sutton. The model's intellectual lineage includes the Biden-era interest in international reference pricing, but its formal NPRM posture means the current administration retains full discretion over whether to finalize, modify, or withdraw the rule.

The Trump administration's prior (first-term) engagement with international reference pricing — including the Most Favored Nation (MFN) model proposed in 2020, which was ultimately blocked in litigation — creates both precedent and political complexity. GUARD's design through the CMMI Section 1115A authority rather than direct drug pricing regulation mirrors the MFN structural approach, though it is limited to the Part D rebate calculation rather than direct payment rate-setting.

The involvement of DOGE (Department of Government Efficiency) in federal spending scrutiny creates an additional variable: a model that projects net savings to the Medicare SMI Trust Fund may receive favorable treatment in an administration focused on deficit reduction, while the pharmaceutical industry opposition that derailed MFN in the first term remains a potent counterweight. Executives should watch the comment period results and any agency response documents closely for signals about whether GUARD will be finalized in its proposed form, substantially revised, or quietly shelved.

Market Transformation Implications

The 17 therapeutic categories covered under GUARD span virtually every high-expenditure drug class in Part D: antineoplastics, cardiovascular agents, blood glucose regulators, immunological agents, antivirals, antipsychotics, and others. This is not a narrow pilot targeting a single drug class. The inclusion of sole-source drugs and sole-source biologics — by definition, products without generic or biosimilar competition — means GUARD targets precisely the segment of the market where manufacturers have the greatest pricing leverage and where the international price gap is historically widest.

If finalized and implemented as proposed, GUARD would represent the most consequential structural intervention in Part D drug pricing since the Inflation Reduction Act's negotiation and inflation rebate provisions. Its five-year performance period (January 1, 2027 through December 31, 2031) would generate pricing precedent and claims data that could inform permanent legislative or regulatory action beyond the model itself. The continuation of rebate invoicing and reconciliation into 2033 extends the financial tail and administrative complexity for manufacturers well beyond the formal performance window.

---

2. Model Architecture and Payment Structure

Participation Structure

GUARD's participant universe is defined with unusual specificity: manufacturers of drugs covered by Medicare Part D are the sole participant category. This is a manufacturer-facing mandatory model — a design that removes provider and plan choice from the equation and places the compliance burden and financial obligation entirely on pharmaceutical companies whose products appear on the Medicare Part D Drug Inflation Rebate Program drug list.

The mandatory nature of the model is operationally significant. Unlike voluntary CMMI models where participation rates and selection bias are constant analytical concerns, GUARD would compel participation by any manufacturer whose qualifying drug is selected for inclusion. This design mirrors the structure of the existing Part D Inflation Rebate Program itself, which is also non-elective for manufacturers.

Eligible drug criteria involve two filters applied in combination:

1. The drug must be a sole-source drug or sole-source biologic — meaning no generic equivalent or interchangeable biosimilar has entered the market.
2. The drug must fall within one of 17 specified therapeutic categories.

The 17 therapeutic categories are:

Therapeutic Category
Analgesics
Anticonvulsants
Antidepressants
Antimigraine Agents
Antineoplastics
Antipsychotics
Antivirals
Bipolar Agents
Blood Glucose Regulators
Cardiovascular Agents
Central Nervous System Agents
Gastrointestinal Agents
Genetic or Enzyme or Protein Disorder: Replacement or Modifiers or Treatment
Immunological Agents
Metabolic Bone Disease Agents
Ophthalmic Agents
Respiratory Tract/Pulmonary Agents

Geographic Scope

GUARD would not operate nationally from launch. The model would be implemented in randomly selected geographic areas representing 25% of people who have a Medicare Part D plan. This geographic stratification serves the CMMI's statutory evaluation obligation under Section 1115A — the randomly selected intervention and comparison areas allow CMS to construct a valid counterfactual for assessing GUARD's causal impact on drug spending and beneficiary outcomes. Manufacturers with national sales will still face rebate obligations in the selected areas, making internal tracking of geographic claim-level data a compliance requirement.

Payment Methodology and Rebate Mechanism

The core payment mechanism is a rebate assessed against manufacturers when a drug's U.S. price exceeds the international benchmark. Key structural elements:

Benchmark construction: The international benchmark will be derived from one of two data sources:

• Manufacturer-reported international pricing information, submitted directly by the manufacturer, or
• Pricing information available to CMS for countries that meet both a GDP per capita threshold and a minimum real economy size threshold

The dual-source approach preserves CMS's ability to construct benchmarks even when manufacturers do not self-report, reducing the risk of strategic non-disclosure undermining the model's function. The specific GDP per capita and real economy size thresholds are defined in the NPRM but were not elaborated beyond this structural description in the CMS model page.

Rebate flow: Rebates paid by manufacturers flow directly to the Medicare Supplementary Medical Insurance (SMI) Trust Fund — not to plans, PBMs, or beneficiaries. This is the same routing used by the existing Part D Inflation Rebate Program. The SMI Trust Fund receipt does not translate directly into beneficiary premium relief within the model itself, though aggregate Trust Fund savings can influence Part D program financing over time.

Relationship to existing Part D Inflation Rebate Program: GUARD does not replace the existing inflation rebate program; it tests an alternative calculation methodology for the rebate amount. The structure — mandatory rebate when price exceeds benchmark, paid to the SMI Trust Fund — is preserved from existing law. What changes is the reference benchmark: international rather than domestic.

Performance Measures and Quality Requirements

The source documents do not specify discrete quality metrics, performance measures, or quality scoring methodologies applicable to manufacturer participants. The model's stated quality objective — preserving or enhancing beneficiaries' quality of care — is framed as an outcome CMS expects GUARD to produce through improved drug affordability and adherence, rather than as a measured performance requirement imposed on manufacturers. Because providers are not participants, there are no clinical quality measures, patient experience surveys, or utilization targets attached to the model in the manner typical of provider-facing CMMI models.

Timeline

Milestone	Date
NPRM published	Federal Register (prior to comment deadline)
Public comment period closes	February 23, 2026
Model launch (performance period begins)	January 1, 2027
Performance period ends	December 31, 2031
Rebate invoicing and reconciliation concludes	2033
Total performance period duration	5 years
Post-period financial tail	~2 years (2032–2033)

Key Structural Distinctions from Provider-Facing Models

Feature	GUARD	Typical Provider-Facing CMMI Model
Participant type	Drug manufacturers	Hospitals, ACOs, physician groups, MA plans
Participation basis	Mandatory	Voluntary or mandatory (varies)
Payment mechanism	Manufacturer rebate to SMI Trust Fund	Shared savings/losses, bundled payments, capitation
APM/MIPS qualification	No	Often yes (Advanced APM or MIPS APM)
Quality measurement	Not specified for manufacturers	Defined quality measure sets
Geographic application	25% of Part D population (randomly selected)	Varies widely
Beneficiary coverage	Medicare Part D enrollees	Medicare FFS, MA, or mixed

Compliance and Administrative Implications for Manufacturers

Manufacturers operating in the 17 therapeutic categories with sole-source products in Part D should treat GUARD finalization as a high-priority pricing and compliance planning scenario regardless of whether the current NPRM is finalized in its proposed form. The existence of the model as a formal NPRM signals CMS's institutional appetite for international reference pricing in Part D, and the comment period through February 23, 2026 represents the primary near-term opportunity to shape the model's final structure. Manufacturers should assess which products fall within the therapeutic category scope, model potential rebate liability under plausible international benchmark scenarios, and engage the comment process with data on international pricing dynamics and access conditions in benchmark-eligible countries.

---

This analysis is based exclusively on the CMS GUARD Model page (last modified December 29, 2025). The model remains in proposed rulemaking status as of the date of this brief. Finalization, modification, or withdrawal of the NPRM will materially alter the analysis presented here. ValuesEdge will publish updated analysis upon any significant regulatory action.